MEG
CRL icon

Millstone Evans Group’s Charles River Laboratories CRL Stock Holding History

Millstone Evans Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.63K Hold
16
– – ﹤0.01% 720
2026
Q1 		$2.76K Hold
16
– – ﹤0.01% 725
2025
Q4 		$3.19K Hold
16
– – ﹤0.01% 705
2025
Q3 		$2.5K Buy
+16
New +$2.54K ﹤0.01% 717

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Millstone Evans Group's CRL Position: Q2 2026 in Review

Millstone Evans Group held its Charles River Laboratories (CRL) position steady in Q2 2026 at 16 shares worth $3.63K. The position accounts for ﹤0.01% of the portfolio, ranked #720.

Millstone Evans Group first reported a position in CRL in Q3 2025 and has held it in 4 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Millstone Evans Group held 16 shares of Charles River Laboratories worth $3.63K as of Q2 2026.
  • Millstone Evans Group left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #720 holding.
  • Millstone Evans Group first reported a position in Charles River Laboratories in Q3 2025 and has held it in 4 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.